The properdin system and immunity. VI. The inactivation of Newcastle disease virus by the properdin system. 1956

H S GINSBERG, and L PILLEMER, and R J WEDGWOOD

Detailed experiments are presented which indicate that the properdin system is an inhibitor of Newcastle disease virus. Viral inhibition required all known components of the properdin system: properdin, all four components of complement and magnesium; the removal of any one constituent resulted in a loss of inhibition; the replacement of the constituent restored antiviral effect. The inhibition of virus was temperature-dependent. The process of inhibition by serum resulted in a decrease in the amount of properdin available in the serum without any measurable effect on the components of complement. The prolonged incubation of inactive serum-virus mixtures with cation-exchange resin resulted in the restoration of some, but not all, of the hemagglutinating activity of the virus. The requirements of the properdin system and the implication of these findings were discussed.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D009521 Newcastle Disease An acute febrile, contagious, viral disease of birds caused by an AVULAVIRUS called NEWCASTLE DISEASE VIRUS. It is characterized by respiratory and nervous symptoms in fowl and is transmissible to man causing a severe, but transient conjunctivitis. Disease, Newcastle
D009522 Newcastle disease virus The most well known avian paramyxovirus in the genus AVULAVIRUS and the cause of a highly infectious pneumoencephalitis in fowl. It is also reported to cause CONJUNCTIVITIS in humans. Transmission is by droplet inhalation or ingestion of contaminated water or food. Avian Paramyxovirus 1,Paramyxovirus 1, Avian
D011414 Properdin A 53-kDa protein that is a positive regulator of the alternate pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It stabilizes the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb) and protects it from rapid inactivation, thus facilitating the cascade of COMPLEMENT ACTIVATION and the formation of MEMBRANE ATTACK COMPLEX. Individuals with mutation in the PFC gene exhibit properdin deficiency and have a high susceptibility to infections. Complement Factor P,Factor P, Complement
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012712 Serum Globulins All blood proteins except albumin ( Euglobulin,Euglobulins,Pseudoglobulin,Pseudoglobulins,Serum Globulin,Globulin, Serum,Globulins, Serum

Related Publications

H S GINSBERG, and L PILLEMER, and R J WEDGWOOD
February 1971, Virology,
H S GINSBERG, and L PILLEMER, and R J WEDGWOOD
January 1976, Archives of virology,
H S GINSBERG, and L PILLEMER, and R J WEDGWOOD
March 1970, Applied microbiology,
H S GINSBERG, and L PILLEMER, and R J WEDGWOOD
September 1955, Science (New York, N.Y.),
H S GINSBERG, and L PILLEMER, and R J WEDGWOOD
April 1953, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
H S GINSBERG, and L PILLEMER, and R J WEDGWOOD
May 1956, The Journal of experimental medicine,
H S GINSBERG, and L PILLEMER, and R J WEDGWOOD
January 1958, Attualita in ematologia,
H S GINSBERG, and L PILLEMER, and R J WEDGWOOD
January 1956, The Journal of experimental medicine,
H S GINSBERG, and L PILLEMER, and R J WEDGWOOD
January 1960, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!